ICU Medical/$ICUI

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About ICU Medical

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

Ticker

$ICUI
Primary listing

Industry

Health Care Equipment & Supplies

Employees

15,000

ISIN

US44930G1076

ICU Medical Metrics

BasicAdvanced
$3.3B
-
-$3.83
0.88
-

What the Analysts think about ICU Medical

Analyst ratings (Buy, Hold, Sell) for ICU Medical stock.

Bulls say / Bears say

ICU Medical's joint venture with Otsuka Pharmaceutical Factory, completed in May 2025, creates one of the largest global IV solutions manufacturing networks, enhancing supply chain resiliency and innovation in North America. (icumed.com)
The FDA's clearance of ICU Medical's Plum Solo™ and Plum Duo™ precision IV pumps in April 2025 introduces a new category of infusion devices with ±3% accuracy, potentially increasing market share. (icumed.com)
StockNews.com upgraded ICU Medical's rating to 'Buy' in March 2025, reflecting positive investor sentiment and confidence in the company's growth prospects. (americanbankingnews.com)
The FDA issued a warning letter to ICU Medical in April 2025 for failing to submit premarket notifications for changes to infusion pumps, indicating potential regulatory challenges. (medtechdive.com)
ICU Medical announced the permanent closure of its Oakdale, Minnesota facility in July 2024, resulting in 83 layoffs, which may signal operational challenges. (medtechdive.com)
The company has faced multiple recalls and quality issues since acquiring Smiths Medical in 2022, potentially affecting its reputation and financial performance. (medtechdive.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.

ICU Medical Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ICU Medical Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ICUI

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs